Promising Outlook for Lexicon Pharmaceuticals’ LX9211 as a Novel Treatment for Diabetic Peripheral Neuropathic Pain
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LXRX stock, giving a Buy rating yesterday.Invest with Confidence: ...
bovnews22h
What’s Driving Lexicon Pharmaceuticals Inc (LXRX) Stock’s 5.16% Surge Over the Past Month?
Lexicon Pharmaceuticals Inc’s Profitability and Valuation Ratios Lexicon Pharmaceuticals Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of ...